December 20th 2021, 8:00pm
Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.
December 12th 2021, 8:00pm
Study results showed that pathologic complete response rates were not significantly different between Black and White patients with high-risk breast cancer, but disparities still exist for other treatment outcomes.
December 11th 2021, 3:00pm
Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.
December 10th 2021, 10:00pm
A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.
December 10th 2021, 5:00pm
The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.
December 10th 2021, 2:00pm
Early-phase study results showed that treatment with a novel drug elicits promising outcomes in patients with advanced or metastatic triple-negative breast cancer.
December 9th 2021, 10:00pm
Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.
December 9th 2021, 8:00pm
Treatment modifications in the pre-surgery setting led to a lower rate of pathologic complete response in Black patients with breast cancer, the researchers found.
December 8th 2021, 10:00pm
The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
December 8th 2021, 4:00pm
Researchers hypothesized that metformin — a medication that helps lower insulin levels in patients with diabetes and is associated with inducing weight loss — might improve breast cancer outcomes.
Broken Yet Unbreakable: My Previvor Journey and the Power of Symbolism
My Imaginary Fear of Cancer Recurrence
How Multidisciplinary Care Impacts Prostate Cancer Treatment
A New Frontier in Melanoma Treatment